Salary Range:CHF115,500.00 - CHF214,500.00 BandLevel 5 Job Description Summary#LI-Hybrid Location: Basel, Switzerland Join Novartis Internal Audit at the forefront of technology innovation, where you will help safeguard and shape the future of data, Artificial Intelligence, cybersecurity and
The Opportunity We are supporting a major data platform transformation within a banking environment, moving from a legacy SQL Server and SSIS-based setup to a modern, scalable architecture built on dbt, Dagster, and OpenShift. This role is not
Join MDPIs FP&A and Corporate Finance team as an FP&A Analyst, where you will transform financial data into strategic insights that drive business decisions. Working on-site in Basel, you will collaborate with finance teams across our European and
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Digital Solutions Finance & Tax (m/f/d) YOUR TASKS AND RESPONSIBILITIES As a digital solutions expert with a strong foundation in both computer science and finance, you lead and enable the digital transformation of finance and transfer
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
The Opportunity We are supporting a major data platform transformation within a banking environment, moving from a legacy SQL Server and SSIS-based landscape to a modern data platform based on dbt, Dagster, and OpenShift . This is an excellent opportunity
Role Overview Location: Basel, Switzerland Contract Duration: 3 years, with possible extension Experience Required: 3+ years Industry Experience: Utilities & Energy, Telecommunications, Banking & Financial Services, Information Technology & Services. Core Responsibilities Mobile Application Development: Develop, implement
Location: Basel, Switzerland Contract Duration: 3 years, with possible extension Experience Required: 3+ years. Industry Experience: Utilities & Energy (Energie & Wasserversorgung) or Telecommunications or Banking & Financial Services or Information Technology & Services Role Overview We
Concur & Card Application Lead Location: San Jose, Costa Rica Join Lonza in a global role where you will own and evolve our SAP Concur Expense platform and Corporate Card Program. This is an exciting opportunity to